For All The Latest Thailand Medical News, COVID-19 News, Long COVID News, H5N1 News, Research News, Health News, Hospital News, Herb News, HIV News, Cancer News, Diabetes News, Alzheimer News, Anti-Aging News, Mental Health News, etc

Medical News - Germany   Jun 12, 2023  3 months, 1 week, 5 days, 23 hours, 34 minutes ago

BioNTech Faces Groundbreaking Lawsuits in Germany Over COVID-19 Vaccine. Hundreds Of Cases Being Brought Up With Thousands More To Come!

facebook sharing button Share
twitter sharing button Tweet
linkedin sharing button Share
BioNTech Faces Groundbreaking Lawsuits in Germany Over COVID-19 Vaccine. Hundreds Of Cases Being Brought Up With Thousands More To Come!
Medical News - Germany   Jun 12, 2023  3 months, 1 week, 5 days, 23 hours, 34 minutes ago
German pharmaceutical giant defends itself in landmark court case as hundreds of compensation claims loom with thousands more planning to file legal suits as well!
Medical News: In a dramatic turn of events, BioNTech, the renowned German pharmaceutical company, is facing a series of lawsuits alleging severe side effects caused by its COVID-19 vaccine. The first court hearing, set to take place on Monday, marks a pivotal moment in the battle between those who suffered adverse effects from the COVID-19 vaccines and vaccine manufacturers. With the potential for thousands of claims, the outcome of these lawsuits could have far-reaching implications for both BioNTech and the vaccination landscape as a whole.

A Wave of Lawsuits
The lawsuit, filed by a middle-aged healthcare worker, seeks compensation of €150,000 ($161,000) for bodily harm allegedly caused by the vaccine. Among her claims are upper-body pain, swelling in the extremities, fatigue, and sleep disorders. This case is one of many brought forth by Rogert & Ulbrich, a prominent law firm that has filed approximately 250 lawsuits against BioNTech for clients who claim to have suffered adverse effects from the vaccine.
The Mainz-based Casar-Preller and Caesar-Preller law firms have also entered the fray, filing 100 lawsuits against the company. These claims represent the largest compensation wave BioNTech has encountered globally since the COVID-19 outbreak. Given that BioNTech produced approximately three-quarters of the 224 million vaccine doses administered in Germany, it is unsurprising that the majority of claims are being directed towards the pioneering mRNA technology used by the company.
The Battle Begins
The German court hearing on Monday will be a groundbreaking event, serving as the litmus test for the credibility of these compensation claims. The case has drawn significant attention, fueled by the controversial figure of Tobias Ulbrich, head of Rogert & Ulbrich law firm. Ulbrich has been vocal in his criticism of vaccine makers, utilizing social media platforms to express his concerns. However, BioNTech firmly stands by its product, asserting that the claims are "baseless" and lacking evidence.
BioNTech's Defense
BioNTech, a publicly listed company, has undergone rigorous scrutiny to ensure the safety and efficacy of its COVID-19 vaccine. The company states that after administering over 1.5 billion doses worldwide, including 64 million in Germany alone, no additional side effects beyond those already listed in the product information have been detected. BioNTech claims that the benefits of its vaccine outweigh any potential risks and has chosen not to allocate provisions for compensation claims.
Examining the Science
European Union regulators and German vaccine assessment bodies have extensively assessed the risk-benefit profile of BioNTech's vaccine. The European Medicines Agency (EMA) has reiterated its confidence in the safety and effectiveness of the vaccine, emphasizing the positive impact vaccines have had on saving lives during the pandemic. While rare side effects have been reported, such as neurological complications and heart inflammation, the EMA a sserts that the benefits far outweigh the risks.
However emerging studies reported in various Medical News coverages are showing that the vaccines are capable of causing a lot of long-term damage especially to heart and vascular tissues with many at risk for heart issues and strokes which can be fatal. There is also a list of hundreds of adverse events that these vaccines can cause.
The Burden of Proof
The burden of proof lies with the claimants in German law, and Rogert & Ulbrich are determined to present strong cases in court. They argue that the compensation they can charge is capped at approximately €7,000 per case and is typically covered by their clients' insurance. Despite accusations of opportunism, the law firms insist that they are fighting for the well-being of those who feel they have been harmed by the vaccine.
Implications and the Way Forward
While the outcome of these lawsuits remains uncertain, the proceedings have undoubtedly heightened concerns surrounding vaccine side effects. BioNTech's courtroom battle may impact public perception of COVID-19 vaccinations and the liability faced by pharmaceutical companies. Moreover, these cases may have broader implications for the future development and distribution of vaccines, as well as the regulatory frameworks in place to assess their safety.
The BioNTech lawsuits are unfolding against a backdrop of vaccine hesitancy and skepticism fueled by reports of adverse effects. Critics argue that the high number of compensation claims could further erode public trust in vaccines and hinder efforts to achieve widespread vaccination coverage, ultimately prolonging the COVID-19 pandemic.
The legal battle between BioNTech and the claimants will serve as an opportunity to scrutinize the evidence presented and determine the validity of the compensation claims. The court's decision will likely shape the future trajectory of similar cases and establish a precedent for liability in vaccine-related adverse events.
Irrespective of the outcome, this legal battle underscores the importance of transparent communication, public education, and robust monitoring systems to ensure vaccine safety. It highlights the need for continuous scientific research, regulatory oversight, and public confidence-building efforts to foster trust in vaccination programs.
Moving forward, it is crucial for governments, healthcare authorities, and pharmaceutical companies to collaborate in addressing public concerns, providing accurate information especially with regards to studies and clinical trials, and promptly addressing any legitimate safety concerns. Open dialogue and transparency can help bridge the gap between public apprehension and the urgent need for vaccination to mitigate the impact of the ongoing pandemic.
For the latest Medical News, keep on logging to Thailand Medical News.


Sep 25, 2022  1 year ago
Source: Medical News - SARS-CoV-2 Fall And Winter 2022 Variant Collections
Sep 08, 2022  1 year ago
Source- Medical News - COVID-19 Research - Impaired Pain Modulation
Aug 04, 2022  1 year ago
Source: Medical News - SARS-CoV-2 & Cancer
Aug 13, 2020  3 years ago
Source: Supplements For COVID-19
Feb 05, 2020  4 years ago
Source : Thailand Medical news